FDLI Off-Label Promotion Discussion Ventures Into “Abstract” Territory
This article was originally published in The Gray Sheet
Executive Summary
Companies should request records of FDA correspondence related to premarket notification when weighing the purchase of another firm's 510(k), attorney Jeffrey Gibbs advised during a Sept. 13-14 Food & Drug Law Institute meeting in Washington, D.C